Global Cholesterol Testing Products and Services Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

What is the Cholesterol Testing Products and Services Market Size and Growth Rate?

• As per Data Bridge Market Research analysis, the cholesterol testing products and services market was valued at USD 10.95 billion in 2025 and is projected to reach USD 14.47 billion by 2033, growing at a CAGR of 3.55% from 2026 to 2033.
• The market is experiencing consistent growth driven by the rising prevalence of cardiovascular diseases, increasing emphasis on preventive healthcare, growing geriatric population, and continuous advancements in cholesterol testing technologies and diagnostic solutions.
• The increasing need for early detection and regular monitoring of high cholesterol, combined with growing awareness of cardiovascular risk factors such as obesity, diabetes, physical inactivity, and hypertension, is encouraging greater adoption of cholesterol testing products and services. Testing kits, laboratory-based tests, and convenient point-of-care and home-testing solutions are increasingly supporting accessible and routine cholesterol monitoring.

Market Size & Forecast

• Global Market Value (2025): USD 10.95 Billion
• Expected Market Value (2033): USD 14.47 Billion
• Forecast CAGR (2026–2033): 3.55%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

What are the Major Takeaways of the Cholesterol Testing Products and Services Market?

• North America dominated the cholesterol testing products and services market with the largest revenue share of 39.6% in 2025, supported by advanced healthcare infrastructure, high cardiovascular disease prevalence, and strong investments in diagnostic technologies
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 9.7% from 2026 to 2033, fueled by rising awareness of cardiovascular health, increasing lifestyle-related diseases, rapid urbanization, and improvements in healthcare infrastructure.
• The testing kits segment led the market with a 45.8% share in 2025, driven by their convenience, user-friendliness, and suitability for home-based cholesterol monitoring.
• Testing strips are the fastest-growing product type, projected to register a CAGR of 9.3%, reflecting the surge in preference for rapid and convenient cholesterol monitoring.
• The total cholesterol tests segment dominated the test type category with a 38.6% revenue share in 2025, led by its widespread use in routine health examinations and preventive cardiovascular screening.
• Geriatric accounted for 46.9% of the market share in 2025, preferred by the increasing prevalence of high cholesterol and cardiovascular diseases among older adults
• The obesity segment is the fastest-growing application category, with a CAGR of 10.1%, driven by increasing prevalence of obesity and its close association with dyslipidemia and cardiovascular risk.

Report Scope and Cholesterol Testing Products and Services Market Segmentation

What is the Key Trend in the Cholesterol Testing Products and Services Market?

• Home-based and point-of-care cholesterol testing is increasingly gaining traction as consumers and healthcare providers seek convenient, rapid, and accessible lipid screening solutions outside conventional laboratory settings.
• For instance, in August 2025, Barts Health expanded a seven-minute cholesterol testing service across East London pharmacies, enabling rapid lipid testing and 10-year cardiovascular risk assessment in community settings, demonstrating the growing shift toward convenient, pharmacy-based cholesterol screening.
• Digital connectivity is increasingly being integrated with cholesterol testing devices, enabling test results to be recorded, shared with healthcare professionals, and incorporated into broader cardiovascular risk-management workflows.
• Pharmacies and community healthcare settings are increasingly providing cholesterol screening services, expanding access to preventive cardiovascular testing and reducing dependence on hospital-based diagnostic facilities.
• For instance, in January 2026, Barts Health expanded its free seven-minute cholesterol testing programme to 70 East London pharmacies, with around 1,000 people already tested and 163 identified as being at high risk of heart attack or stroke, highlighting the growing adoption of decentralized cholesterol testing.
• As healthcare systems continue prioritizing preventive cardiovascular care and accessible diagnostics, adoption of rapid, home-based, and pharmacy-based cholesterol testing is expected to accelerate, strengthening decentralized testing across the market.

What are the Key Drivers of the Cholesterol Testing Products and Services Market?

• The rising prevalence of elevated cholesterol and cardiovascular risk factors has significantly increased demand for routine cholesterol screening and lipid-profile testing across adult and high-risk populations.
• For instance, in March 2026, the American Heart Association and American College of Cardiology released updated cholesterol-management guidance recommending earlier screening and greater use of advanced lipid measurements such as apolipoprotein B and lipoprotein(a), expanding demand for comprehensive cholesterol testing and cardiovascular risk assessment.
• Healthcare providers, diagnostic laboratories, and pharmacies are expanding preventive screening programs to identify asymptomatic individuals with elevated cholesterol and support earlier cardiovascular risk management.
• For instance, in November 2025, cardiologists at the Lipidology Conference in India emphasized regular lipid-profile screening for adults and recommended advanced tests such as apolipoprotein B and non-HDL cholesterol for high-risk individuals, highlighting the growing focus on earlier and more comprehensive cholesterol assessment.
• With cardiovascular risk management increasingly emphasizing early detection and regular monitoring, cholesterol testing products and services will remain essential for identifying dyslipidemia and supporting timely preventive interventions.

Which Factors are Challenging the Growth of the Cholesterol Testing Products and Services Market?

• The accuracy and reliability of cholesterol testing products can vary across devices and testing methods, creating challenges for manufacturers seeking to deliver consistent results across home, point-of-care, and laboratory environments.
• For instance, in February 2025, an article published in the National Library of Medicine highlighted concerns about the accuracy of point-of-care cholesterol tests, noting that poor accuracy could result in false reassurance, overdiagnosis, or inappropriate treatment, creating challenges for wider adoption of decentralized testing.
• Incorrect sample collection, improper handling of test strips, and failure to follow testing instructions can affect results, potentially reducing consumer confidence in self-administered cholesterol testing.
• Regulatory requirements and quality-control expectations for cholesterol testing devices can increase development and compliance costs, particularly for manufacturers introducing portable and over-the-counter testing solutions.
• For instance, in April 2024, the U.S. FDA raised concerns about the accuracy and performance of some laboratory-developed tests, noting that certain in-vitro diagnostic tests may produce inaccurate results or perform less reliably than FDA-authorized tests, highlighting the importance of regulatory oversight and quality control in cholesterol and other diagnostic testing.
• The need for reliable test performance, regulatory compliance, and appropriate interpretation of results continues to challenge market participants, particularly as adoption expands from clinical laboratories toward decentralized and consumer-driven testing environments.

How is the Cholesterol Testing Products and Services Market Segmented?

The cholesterol testing products and services market is segmented on the basis of product, test type, age group, application, and end user.

• By Product

On the basis of product, the cholesterol testing products and services market is segmented into testing kits, testing strips, and other products. The testing kits segment dominated the market with a 45.8% share in 2025, owing to their convenience, user-friendliness, and suitability for home-based cholesterol monitoring. These kits allow consumers to perform cholesterol assessments without frequent laboratory visits. Their accessibility supports preventive healthcare and regular monitoring among individuals at risk of cardiovascular conditions. Increasing consumer awareness of cholesterol management is further supporting demand for easy-to-use testing solutions. The availability of portable testing kits is also expanding cholesterol monitoring beyond conventional healthcare facilities.

The testing strips segment is projected to register the fastest growth at a CAGR of 9.3% during forecast period, driven by increasing preference for rapid and convenient cholesterol monitoring. Testing strips can be used with portable analyzers, supporting decentralized testing and point-of-care applications. Their simplicity makes them suitable for consumers seeking frequent cholesterol monitoring outside traditional laboratories. Increasing awareness of cardiovascular health is encouraging greater use of convenient testing formats. Technological improvements in digital and multi-use strips are also improving their functionality and consumer appeal. Their portability and relatively low cost support adoption across emerging and developed healthcare markets

• By Test Type

On the basis of test type, the cholesterol testing products and services market is segmented into total cholesterol tests, high-density lipoprotein (HDL) cholesterol tests, low-density lipoprotein (LDL) cholesterol tests, triglyceride tests, and other tests. The total cholesterol tests segment dominated the market with a 38.6% share in 2025, supported by its widespread use in routine health examinations and preventive cardiovascular screening. Total cholesterol testing provides an overall assessment of cholesterol levels and is commonly included in lipid evaluations. It remains an established testing approach across hospitals, clinics, and diagnostic laboratories. Growing awareness of cardiovascular risk is encouraging more individuals to undergo routine cholesterol screening. Healthcare providers also use total cholesterol measurements as part of broader lipid assessments and cardiovascular risk evaluation

The LDL cholesterol tests segment is expected to register the fastest growth at 9% CAGR during forecast period, supported by increasing clinical emphasis on LDL as a major modifiable cardiovascular risk factor. LDL testing is increasingly used to evaluate cardiovascular risk and monitor responses to cholesterol-lowering interventions. Growing awareness of dyslipidemia is encouraging more frequent assessment of LDL levels among high-risk populations. The increasing prevalence of diabetes, obesity, and cardiovascular conditions is further expanding the need for LDL monitoring. Improvements in laboratory analyzers and point-of-care technologies are supporting faster and more accessible LDL measurements. Greater emphasis on individualized cholesterol management is also strengthening demand for targeted LDL assessment.

• By Age Group

On the basis of age group, the cholesterol testing products and services market is segmented into pediatric, adult, and geriatric populations. The geriatric segment dominated the market with a 46.9% share in 2025, primarily due to the increasing prevalence of high cholesterol and cardiovascular diseases among older adults. Aging populations generally require more frequent health assessments and chronic disease monitoring. Cholesterol testing is increasingly incorporated into preventive checkups and cardiovascular risk-management programs for older individuals. The higher incidence of metabolic and cardiovascular conditions among this population further supports testing demand. Growing healthcare utilization among older adults is also increasing the volume of diagnostic testing.

The adult segment is expected to register the fastest growth at 9.5% CAGR during forecast period, driven by rising exposure to lifestyle-related cardiovascular risk factors. Increasing prevalence of obesity, diabetes, physical inactivity, and unhealthy dietary patterns is creating a larger population requiring regular cholesterol assessment. Preventive health screening is becoming increasingly important among working-age adults seeking early identification of cardiovascular risk. Greater awareness of the relationship between elevated cholesterol and heart disease is encouraging routine testing. The expansion of home-based and point-of-care testing is also making cholesterol monitoring more convenient for adults. Increasing integration of lipid testing into primary-care and preventive-health programs is further supporting demand

• By Application

On the basis of application, the cholesterol testing products and services market is segmented into cardiovascular diseases, diabetes, obesity, hyperlipidemia, and others. The cardiovascular diseases segment dominated the market with a 35.5% share in 2025, supported by the strong relationship between abnormal cholesterol levels and cardiovascular risk. Cholesterol testing is routinely used to identify lipid abnormalities associated with heart disease and stroke. The substantial global burden of cardiovascular diseases continues to generate demand for screening and monitoring services. Healthcare providers increasingly incorporate cholesterol testing into cardiovascular risk assessments and preventive-care pathways. Regular testing is also used to monitor patients receiving cholesterol-lowering treatment.

The obesity segment is expected to register the fastest growth at 10.1% CAGR during forecast period, driven by the increasing prevalence of obesity and its close association with dyslipidemia and cardiovascular risk. Obesity can contribute to abnormal lipid profiles, increasing the need for routine cholesterol monitoring. Healthcare providers increasingly incorporate lipid assessments into obesity-management and metabolic-health programs. Growing awareness of obesity-related cardiovascular complications is encouraging earlier screening. The expansion of preventive healthcare is also increasing demand for cholesterol assessments among overweight and obese populations. Increasing availability of convenient testing options is further supporting regular monitoring outside traditional laboratory environments.

• By End User

On the basis of end user, the cholesterol testing products and services market is segmented into hospitals and clinics, diagnostic laboratories, and other end users. The hospitals and clinics segment dominated the market with a 39.1% share in 2025, supported by high patient volumes, established diagnostic infrastructure, and availability of trained healthcare professionals. Hospitals and clinics routinely conduct cholesterol testing as part of health examinations and cardiovascular assessments. These facilities also perform lipid monitoring for patients with diabetes, obesity, cardiovascular diseases, and hyperlipidemia. The integration of cholesterol testing into chronic disease management supports recurring demand from these healthcare settings. Increasing adoption of point-of-care diagnostic technologies is further improving testing accessibility within clinical facilities.

The diagnostic laboratories segment is expected to register the fastest growth at a 10.6% CAGR during forecast period, supported by increasing demand for comprehensive and reliable lipid testing. Diagnostic laboratories provide high-throughput testing capabilities that enable healthcare providers to process large volumes of cholesterol samples efficiently. Growing preventive screening programs are increasing the number of patients undergoing routine lipid assessments. Advanced automated analyzers are improving laboratory efficiency and supporting faster turnaround of test results. Increasing demand for detailed lipid profiles and specialized cholesterol measurements is further strengthening laboratory utilization. The continued expansion of diagnostic networks and preventive healthcare services is creating additional testing volumes.

Which Region Holds the Largest Share of the Cholesterol Testing Products and Services Market?

• North America dominated the cholesterol testing products and services market with the largest revenue share of 39.6% in 2025, supported by advanced healthcare infrastructure, high cardiovascular disease prevalence, and strong investments in diagnostic technologies
• The region also benefits from an aging population, strong investments in diagnostic research and development, high awareness of cardiovascular health, and government-supported preventive healthcare initiatives. The growing adoption of point-of-care and home-based cholesterol testing solutions is further improving accessibility, while established healthcare systems and increasing demand for routine cardiovascular screening continue to strengthen North America’s leadership position in the global market.

U.S. Cholesterol Testing Products and Services Market Insight

The U.S. cholesterol testing products and services market is witnessing strong growth due to the high prevalence of cardiovascular risk factors, increasing emphasis on preventive healthcare, and widespread availability of advanced diagnostic infrastructure. The country’s mature healthcare ecosystem, along with increasing adoption of point-of-care, laboratory-based, and home cholesterol testing solutions, is driving demand across hospitals, clinics, pharmacies, and diagnostic laboratories. In addition, growing awareness regarding cholesterol management and regular cardiovascular screening is accelerating testing adoption among adults and high-risk populations.

Asia-Pacific Cholesterol Testing Products and Services Market Insight

The Asia-Pacific cholesterol testing products and services market is expected to witness rapid growth, driven by rising cardiovascular disease burden, increasing healthcare expenditure, and improving diagnostic infrastructure across countries such as China, India, and Japan. Growing awareness regarding preventive cardiovascular care, rising adoption of point-of-care testing technologies, and increasing demand for affordable and accessible screening solutions are supporting regional market expansion. Additionally, the growing presence of diagnostic laboratories, expanding healthcare networks, and increasing availability of home-based testing solutions are accelerating cholesterol testing adoption across the region.

Japan Cholesterol Testing Products and Services Market Insight

The Japan cholesterol testing products and services market is witnessing consistent growth due to the country’s aging population, high healthcare awareness, and strong emphasis on preventive cardiovascular care. Hospitals, clinics, and diagnostic laboratories are increasingly conducting lipid testing for cardiovascular risk assessment and chronic disease management. Moreover, increasing adoption of automated diagnostic systems, point-of-care testing technologies, and convenient health-screening solutions, together with Japan’s advanced healthcare infrastructure, is further contributing to market growth.

China Cholesterol Testing Products and Services Market Insight

The China cholesterol testing products and services market is growing rapidly, driven by increasing cardiovascular disease prevalence, expanding healthcare infrastructure, and rising government emphasis on disease prevention and health management. Growing adoption of automated laboratory diagnostics and point-of-care cholesterol testing across hospitals, clinics, and community healthcare facilities is significantly boosting market demand. In addition, rising healthcare expenditure, increasing awareness regarding dyslipidemia, and expanding access to preventive screening are positioning China as one of the fastest-growing markets for cholesterol testing products and services globally.

U.K. Cholesterol Testing Products and Services Market Insight

The U.K. cholesterol testing products and services market is experiencing steady growth, supported by increasing emphasis on cardiovascular disease prevention, community-based screening, and accessible diagnostic services. Growing adoption of cholesterol testing across general practices, pharmacies, hospitals, and diagnostic facilities is contributing to market growth. Furthermore, expansion of rapid finger-prick testing, preventive health programs, and digital health technologies is improving testing accessibility and convenience, positioning the U.K. as a key market for decentralized cholesterol screening.

Germany Cholesterol Testing Products and Services Market Insight

The Germany cholesterol testing products and services market is expanding steadily due to the country’s advanced healthcare infrastructure, aging population, and strong focus on preventive cardiovascular care. Hospitals, physicians, and diagnostic laboratories increasingly utilize cholesterol testing for routine health examinations, cardiovascular risk assessment, and chronic disease monitoring. Continuous advancements in automated laboratory diagnostics, point-of-care testing, and digital health technologies, along with Germany’s emphasis on early disease detection and healthcare quality, are further driving market growth in the country.

Which are the Top Companies in Cholesterol Testing Products and Services Market?

The cholesterol testing products and services industry is primarily led by well-established companies, including:

• Quest Diagnostics Incorporated (U.S.)
• Labcorp (U.S.)
• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Siemens Healthineers AG (Germany)
• Danaher (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Randox Laboratories Ltd (U.K.)
• Nova Biomedical (U.S.)
• SEKISUI Diagnostics (U.S.)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
• Sysmex Corporation (Japan)
• HORIBA, Ltd. (Japan)
• Eurofins Scientific SE (Luxembourg)
• SYNLAB International GmbH (Germany)
• Unilabs (Switzerland)
• Clinical Reference Laboratory, Inc. (U.S.)
• ACM Global Laboratories (U.S.)
• PTS Diagnostics (U.S.)

What are Latest Developments in Cholesterol Testing Products and Services Market?

• In January 2026, Orange Health Labs launched Orange One, an annual health-testing service that includes cholesterol and lipid-marker testing, allowing customers to access a broad range of diagnostic tests throughout the year under a single subscription-style plan. The launch demonstrates the shift toward continuous and preventive diagnostic services incorporating routine cholesterol monitoring.
• In August 2025, Boots launched 13 new at-home health testing kits in the U.K., including a cholesterol blood test kit, expanding its consumer diagnostic portfolio and enabling customers to test cholesterol levels from home without requiring an initial GP visit. The launch reflects the growing availability of convenient, self-administered cholesterol testing products through major pharmacy retailers
• In March 2025, Boots was highlighted for launching finger-prick lateral-flow tests capable of measuring cholesterol levels, alongside tests for vitamin D and iron. The new testing format was designed to provide consumers with rapid health information from a small blood sample, demonstrating the development of more accessible and convenient cholesterol-testing technologies.
• In October 2024, the Family Heart Foundation launched Cholesterol Connect as a nationwide at-home screening program, providing a free standard lipid panel measuring total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, along with lipoprotein(a) screening. Participants receive a home-testing kit, collect their sample, and return it to a CLIA-certified laboratory, with results available online and optional care-navigation support, demonstrating the expansion of comprehensive cholesterol testing beyond traditional clinical settings
• In July 2024, Babson Diagnostics launched its BetterWay blood-testing system in select pharmacies in Austin and San Antonio, enabling routine laboratory tests including cholesterol testing from just a few drops of capillary blood collected through a finger prick. The system combines a small-volume blood collection process with automated sample preparation and laboratory analysis, supporting more convenient cholesterol testing in community pharmacy settings and reducing reliance on conventional venous blood draws.

SKU-76742